Cargando…

P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study

INTRODUCTION: In this pilot study, we explored sleep biomarker risk probabilities for different neurodegenerative disorder (NDD) phenotypes across a spectrum of NDD patients, compared with controls. METHODS: We analyzed a cohort of patients with different NDD phenotypes who underwent in-home recordi...

Descripción completa

Detalles Bibliográficos
Autores principales: Levendowski, D, Tsuang, D, Neylan, T, Walsh, C, Lee-Iannotti, J, Berka, C, Mazeika, G, Boeve, B, St. Louis, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591739/
http://dx.doi.org/10.1093/sleepadvances/zpad035.107
_version_ 1785124285579264000
author Levendowski, D
Tsuang, D
Neylan, T
Walsh, C
Lee-Iannotti, J
Berka, C
Mazeika, G
Boeve, B
St. Louis, E
author_facet Levendowski, D
Tsuang, D
Neylan, T
Walsh, C
Lee-Iannotti, J
Berka, C
Mazeika, G
Boeve, B
St. Louis, E
author_sort Levendowski, D
collection PubMed
description INTRODUCTION: In this pilot study, we explored sleep biomarker risk probabilities for different neurodegenerative disorder (NDD) phenotypes across a spectrum of NDD patients, compared with controls. METHODS: We analyzed a cohort of patients with different NDD phenotypes who underwent in-home recordings with Sleep Profiler, including Lewy body disease (LBD=20), Alzheimer’s disease dementia (AD=29), and isolated REM sleep behavior disorder (iRBD=19). Controls with an MMSE>28 (CG=61) and patients with Parkinson disease (PD=16) and mild-cognitive-impairment (MCI=41) also participated. We developed a machine-learning classifier that assigned NDD probabilities for LBD, AD, iRBD, and CG. The input variables included: time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Probabilities >50% were assigned “likely”, and for CG>=50% and a NDD group probability 20-50%, the assignment was normal “plus”. Probability assignments were then made for the NDD and CG groups, then further applied to the PD and MCI patient groups. RESULTS: The CG group participants were assigned Normal-Likely=74%, Normal+AD=11%, Normal+iRBD=5%, iRBD-Likely=5%, and AD-Likely=5%. LBD patient distributions were LBD-Likely=70%, iRBD-Likely=5%, AD-Likely=5%, Normal+LBD=5%, Normal+iRBD=5%, Normal+AD=5%, and Normal-Likely=5%. AD group distributions were AD-Likely=71%, LBD-Likely=4%, Normal+AD=14%, Normal+iRBD=4%, Normal-Likely=7%. iRBD patients were characterized with iRBD-Likely=37%, LBD-Likely=5%, AD-Likely=5%, Normal+iRBD=27%, Normal-Likely=26%. PD patients were assigned iRBD-Likely=29%, LBD-likely=14%, AD-Likely=14%, Normal+iRBD=21%, Normal+AD=7%, Normal-Likely=14%. MCI distributions were AD-Likely=45%, LBD-Likely=8%, iRBD-Likely=5%, Normal+AD=21%, Normal-Likely=13%. CONCLUSIONS: For LBD, AD and CG groups, correct risk assignments were >70% while gross misclassifications were <10%. Classification patterns for PD, MCI and iRBD were disbursed in a manner consistent with the range of severities expected in each group.
format Online
Article
Text
id pubmed-10591739
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105917392023-10-24 P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study Levendowski, D Tsuang, D Neylan, T Walsh, C Lee-Iannotti, J Berka, C Mazeika, G Boeve, B St. Louis, E Sleep Adv Poster Discussion Presentations INTRODUCTION: In this pilot study, we explored sleep biomarker risk probabilities for different neurodegenerative disorder (NDD) phenotypes across a spectrum of NDD patients, compared with controls. METHODS: We analyzed a cohort of patients with different NDD phenotypes who underwent in-home recordings with Sleep Profiler, including Lewy body disease (LBD=20), Alzheimer’s disease dementia (AD=29), and isolated REM sleep behavior disorder (iRBD=19). Controls with an MMSE>28 (CG=61) and patients with Parkinson disease (PD=16) and mild-cognitive-impairment (MCI=41) also participated. We developed a machine-learning classifier that assigned NDD probabilities for LBD, AD, iRBD, and CG. The input variables included: time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Probabilities >50% were assigned “likely”, and for CG>=50% and a NDD group probability 20-50%, the assignment was normal “plus”. Probability assignments were then made for the NDD and CG groups, then further applied to the PD and MCI patient groups. RESULTS: The CG group participants were assigned Normal-Likely=74%, Normal+AD=11%, Normal+iRBD=5%, iRBD-Likely=5%, and AD-Likely=5%. LBD patient distributions were LBD-Likely=70%, iRBD-Likely=5%, AD-Likely=5%, Normal+LBD=5%, Normal+iRBD=5%, Normal+AD=5%, and Normal-Likely=5%. AD group distributions were AD-Likely=71%, LBD-Likely=4%, Normal+AD=14%, Normal+iRBD=4%, Normal-Likely=7%. iRBD patients were characterized with iRBD-Likely=37%, LBD-Likely=5%, AD-Likely=5%, Normal+iRBD=27%, Normal-Likely=26%. PD patients were assigned iRBD-Likely=29%, LBD-likely=14%, AD-Likely=14%, Normal+iRBD=21%, Normal+AD=7%, Normal-Likely=14%. MCI distributions were AD-Likely=45%, LBD-Likely=8%, iRBD-Likely=5%, Normal+AD=21%, Normal-Likely=13%. CONCLUSIONS: For LBD, AD and CG groups, correct risk assignments were >70% while gross misclassifications were <10%. Classification patterns for PD, MCI and iRBD were disbursed in a manner consistent with the range of severities expected in each group. Oxford University Press 2023-10-23 /pmc/articles/PMC10591739/ http://dx.doi.org/10.1093/sleepadvances/zpad035.107 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Sleep Research Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Discussion Presentations
Levendowski, D
Tsuang, D
Neylan, T
Walsh, C
Lee-Iannotti, J
Berka, C
Mazeika, G
Boeve, B
St. Louis, E
P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study
title P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study
title_full P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study
title_fullStr P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study
title_full_unstemmed P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study
title_short P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study
title_sort p022 sleep biomarker phenotyping of neurodegenerative disorders using artificial intelligence – a pilot study
topic Poster Discussion Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591739/
http://dx.doi.org/10.1093/sleepadvances/zpad035.107
work_keys_str_mv AT levendowskid p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy
AT tsuangd p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy
AT neylant p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy
AT walshc p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy
AT leeiannottij p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy
AT berkac p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy
AT mazeikag p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy
AT boeveb p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy
AT stlouise p022sleepbiomarkerphenotypingofneurodegenerativedisordersusingartificialintelligenceapilotstudy